Amino GmbH, which produces high-quality pharmaceutical-grade amino acids for pharmaceutical, medical and clinical dietetic nutrition applications, announces plans to double production capacity by building a new facility at its headquarters in Frellstedt, Germany. Amino is investing approximately $35 million to meet the growing demand of current customers and to increase supply and availability for the worldwide pharmaceutical and nutritional market. Construction will begin by March 31 and the new facility will begin operation in 2021.
“We are expanding because we believe in ourselves and we want to offer our services to a broader audience,” said Dr. Lutz Thomas, Managing Director. “We will be an even stronger source for companies in the high-end pharmaceutical grade amino acid market.”
Dr. Thomas said that by building the new facility, Amino will increase production by about 1200 metric tons across all product lines, the complete range of pharmaceutical grade amino acids. Serving Europe, Asia and the Americas, Amino specializes in amino acids for: infusions and injections; active pharmaceutical ingredients for oral applications; pharma-intermediates; pharmaceutical production in cell cultures, and medical nutrition and infant formula.
Amino has registered rapid and consistent annual growth for more than 10 years by adding value beyond the amino acid and helping customers solve their production problems. To that end, Amino has invested heavily in R&D, creating its AminoVation platform to expand its line of products and services and respond even faster and more specifically to customers’ needs.
“We are developing the next generation of products for the next generation of employees and managers,” explained Dr. Thomas. “Building on our current portfolio we are developing amino acid derivatives and other APIs and nutrients.”
“Current growth is exhausting Amino’s production capacity.” said Dr. Thomas and added, “The Company now needs to think bigger and beyond its European base”.
“We plan to expand our marketing worldwide with a focus on the American markets,” said Kai-Philipp Thomas, Manager of Sales & Marketing. “The new facility enables Amino to supply new customers, particularly pharmaceutical companies in the U.S., while also meeting increasing demand from our existing customer base.”
> Show less